| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | T cells with increased immunosuppression resistance | US15713464 | 2017-09-22 | US09976121B2 | 2018-05-22 | Bruno Laugel; Kathrin Skibbe |
| This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment. | ||||||
| 2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | US15559875 | 2016-03-18 | US20180057466A1 | 2018-03-01 | Julia Adam |
| Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) are also described. | ||||||
| 3 | RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS | US14162581 | 2014-01-23 | US20140171487A1 | 2014-06-19 | John M. Yanni; John E. Chatterton; Daniel A. Gamache; Steven T. Miller |
| RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms. | ||||||
| 4 | ＣＯＰＤ及びその他の炎症状態を治療するための組成物及び方法 | JP2017548049 | 2016-03-21 | JP2018510153A | 2018-04-12 | リ ジャン−ドン |
| 本発明は、特に、医薬組成物、及び薬剤(例えば、炎症性肺疾患等の炎症用薬剤)の調製又は治療計画におけるその使用を特徴とする。前記組成物は、以下の少なくとも2つの活性薬剤を含み得る:PDE4を阻害する第1の薬剤(例えば、ロフルミラスト)、及び1又は2以上のPDE4Bバリアント(例えば、PDE4B2)の発現又は活性を阻害する第2の活性薬剤。該組成物及び方法は、PDE4B(例えば、PDE4B2)の望ましくない上方制御を弱め、またこれにより、第1の薬剤(例えば、ロフルミラスト)による治療を改善し得る。例えば、第2の薬剤は、第1の薬剤の有効性を改善し、第1の薬剤の有効用量を減少させ、そうしなければ起こるような(例えば、COPDが増悪した患者において)第1の薬剤に対する耐性を緩和し、第1の薬剤により引き起こされる望ましくない副作用を低減し得るか、或いはPDE4インヒビターを含む治療計画を改善し得る。 | ||||||
| 5 | トリアゾール誘導体およびPDE4活性化体としてその使用 | JP2017567558 | 2016-03-18 | JP2018515594A | 2018-06-14 | アダム ジュリア |
| 長鎖形体サイクリックヌクレオチドホスホジエステラーゼ−4(PDE4)酵素の活性化体である式(I)の化合物を提供する。環式3’,5’−アデノシン一燐酸(cAMP)によって媒介された二次伝達物質応答の低減を要求する病気の治療または予防のための方法でのこれらの化合物の使用も提供する。 | ||||||
| 6 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | US15559728 | 2016-03-21 | US20180042904A1 | 2018-02-15 | Jian-Dong LI |
| The present invention features, inter alia, pharmaceutical compositions and their use in the preparation of a medicament (e.g., a medicament for inflammation, such as an inflammatory lung disease) or in a therapeutic regimen. The compositions can include at least two active agents: a first agent that inhibits PDE4 (e.g., roflumilast) and a second active agent that inhibits the expression or activity of one or more PDE4B variants (e.g., PDE4B2). The compositions and methods will attenuate an unwanted up-regulation of a PDE4B (e.g., PDE4B2) and may thereby improve treatment with the first agent (e.g., roflumilast). For example, the second agent may improve the efficacy of the first agent, decrease the effective dose of the first agent, ameliorate the tolerance to the first agent that would otherwise develop (e.g., in patients with COPD exacerbation), reduce unwanted side effects caused by the first agent, or otherwise improve treatment regimes including a PDE4 inhibitor. | ||||||
| 7 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | US13290632 | 2011-11-07 | US20130116279A1 | 2013-05-09 | Steven P. Govek; Andrew K. Shiau; Stewart A. Noble; David J. Thomas |
| The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators. | ||||||
| 8 | T Cells With Increased Immunosuppression Resistance | US15949018 | 2018-04-09 | US20180298338A1 | 2018-10-18 | Bruno Laugel; Kathrin Skibbe |
| This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment. | ||||||
| 9 | T Cells with Increased Immunosuppression Resistance | US15713464 | 2017-09-22 | US20180010095A1 | 2018-01-11 | Bruno Laugel; Kathrin Skibbe |
| This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment | ||||||
| 10 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders | US15255278 | 2016-09-02 | US09765340B2 | 2017-09-19 | John M. Yanni; Jon E. Chatterton; Daniel A. Gamache; Steven T. Miller |
| RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms. | ||||||
| 11 | RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of CAMP-Related Ocular Disorders | US15255278 | 2016-09-02 | US20170051291A1 | 2017-02-23 | John M. Yanni; Jon E. Chatterton; Daniel A. Gamache; Steven T. Miller |
| RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms. | ||||||
| 12 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders | US14162581 | 2014-01-23 | US09453220B2 | 2016-09-27 | John M. Yanni; John E. Chatterton; Daniel A. Gamache; Steven T. Miller |
| RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms. | ||||||
| 13 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders | US12580663 | 2009-10-16 | US08673873B1 | 2014-03-18 | John M. Yanni; Jon E. Chatterton; Daniel A. Gamache; Steven T. Miller |
| RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms. | ||||||
| 14 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | EP16769518.8 | 2016-03-21 | EP3270921A1 | 2018-01-24 | LI, Jian-dong |
| The present invention features, inter alia, pharmaceutical compositions and their use in the preparation of a medicament (e.g., a medicament for inflammation, such as an inflammatory lung disease) or in a therapeutic regimen. The compositions can include at least two active agents: a first agent that inhibits PDE4 (e.g., roflumilast) and a second active agent that inhibits the expression or activity of one or more PDE4B variants (e.g., PDE4B2). The compositions and methods will attenuate an unwanted up-regulation of a PDE4B (e.g., PDE4B2) and may thereby improve treatment with the first agent (e.g., roflumilast). For example, the second agent may improve the efficacy of the first agent, decrease the effective dose of the first agent, ameliorate the tolerance to the first agent that would otherwise develop (e.g., in patients with COPD exacerbation), reduce unwanted side effects caused by the first agent, or otherwise improve treatment regimes including a PDE4 inhibitor. | ||||||
| 15 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | EP16712412.2 | 2016-03-18 | EP3271338A1 | 2018-01-24 | ADAM, Julia |
| Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5'-adenosine monophosphate (cAMP) are also described. | ||||||
| 16 | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 8B (PDE8B) | EP03772262.6 | 2003-10-25 | EP1601782A2 | 2005-12-07 | GOLZ, Stefan; BRÜGGEMEIER, Ulf; GEERTS, Andreas |
| The invention provides a human PDE8B which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, endocrinological disease, urological disorders, reproduction disorders and metabolic disease. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, endocrinological disease, urological disorders, reproduction disorders and metabolic disease. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE8B as well as pharmaceutical compositions comprising such compounds. | ||||||
| 17 | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 8B (PDE8B) | PCT/EP0311883 | 2003-10-25 | WO2004042077A3 | 2005-01-13 | GOLZ STEFAN; BRUEGGEMEIER ULF; GEERTS ANDREAS |
| The invention provides a human PDE8B which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, endocrinological disease, urological disorders, reproduction disorders and metabolic disease. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, endocrinological disease, urological disorders, reproduction disorders and metabolic disease. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE8B as well as pharmaceutical compositions comprising such compounds. | ||||||
| 18 | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 4A (PDE4A) | PCT/EP0311879 | 2003-10-25 | WO2004042076A2 | 2004-05-21 | GOLZ STEFAN; BRUEGGEMEIER ULF; GEERTS ANDREAS |
| Diagnostics and Therapeutics for Diseases Associated with Human Phosphodiesterase 4A (PDE4A)Abstract of DisclosureThe invention provides a human PDE4A which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, inflammation, gastroenterological diseases and endocrinological disease. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, inflammation, gastroenterological diseases and endocrinological disease. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE4A as well as pharmaceutical compositions comprising such compounds. | ||||||
| 19 | PHOSPHODIESTERASE 4D IN THE RYANODINE RECEPTOR COMPLEX PROTECTS AGAINST HEART FAILURE | PCT/US2005045914 | 2005-12-15 | WO2006071603A9 | 2007-03-29 | MARKS ANDREW R; LEHNART STEPHAN E; WEHRENS XANDER H T; REIKEN STEVEN; CONTI MARCO; JIN CATHERINE S L |
| The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. | ||||||
| 20 | PHOSPHODIESTERASE 4D IN THE RYANODINE RECEPTOR COMPLEX PROTECTS AGAINST HEART FAILURE | PCT/US2005045914 | 2005-12-15 | WO2006071603A2 | 2006-07-06 | MARKS ANDREW R; LEHNART STEPHAN E; WEHRENS XANDER H T; REIKEN STEVEN; CONTI MARCO; JIN CATHERINE S L |
| The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. | ||||||
QQ群二维码
意见反馈
意见反馈